## Index

advocate for franchisees 154  
ageing business owner, business exits 44  
agency theory 8, 229–30  
age-specific death rates for organizations 30  
allergy, intellectual property 77, 79  
allergy program of ImmuLogic 75–7  
angel investors 223  
appointment missing 140  
Arkwright’s textile mill, 1771 15  
attitude and behavioral intention 172  
avto producers, US, decline 22–3  
avtimmune research program 63, 77–9  
partnership of ImmuLogic and Merck 78–9  
automobile industry  
Europe 26  
French and British, rapid sustained growth 26  
US, entry and decline 23–4  
autonomy influence against retirement 168–9

Bamburg, Jill  

bankruptcy 173  
beer brewer decline, US 23  
behavior  
acceptable, in workplace 147  
control 164  
disengagement, coping behavior 191

Ben & Jerry’s ice cream company 8  
all-natural ingredients 221  
‘selling out’ 221–2  
Unilever acquirement, 2000 215, 235, 240

Benefit Corporation in state law 215, 223  
biographical information of individuals in organization 72  
biotechnology firms founding by scientific individual from  
ImmuLogic 83  
birth rates lowering 157  
Body Shop  
more than what it sells 219  
sale to L’Oréal, 2006 219–20  
bridge employment option  
full or part-time after retirement 158  
Burt’s Bees, sale to Clorox 215  
business and economic theories, alternatives 207  
business angels 5, 223  
investment in entrepreneurial firms 89  
business bankruptcy, exit route 13  
business characteristics 107, 135  
Business Employment Dynamics Database  
measuring business births and deaths 32–3

business exit  
and business failure, coterminous 47  
from gendered perspective 42–59  
business founding rates  
increase or decrease reasons 22  
business-level consequences of retirement 178  
business premises, importance of 250  
business tracking from birth 107  
business transfer failure  
emotional and psychological aspects 184–5  
business, ultimate purpose for 155–6  
businesses, necessity-driven 204  
buyback  
entrepreneurial firm buying VC investor’s shares 95  
cancer death of business partner 141  
Cantab Pharmaceuticals, UK-based 79  
capitalist economic systems, business role in 37
captive VCs (CVCs) 102
cash acquisition method of payment 95
cash reserves for exited firm, results of exit 231
cat allergies, ImmuLogic 75, 77
CATVAX intellectual property, ImmuLogic 77
censoring of an observation 112
children as successors, choice jealousy and rivalry 187
Chouniard, Yvon founder of Patagonia 218
decision sharing positives and negatives of young worker 131
delegation of authority, importance of 145–6
denial, coping behavior 191
diabetes treatments 78
digital information 17 late 20th century 15
direct mail campaigns 133–4
discovery, evaluation, exploitation of opportunities 216
disengagement, entrepreneurial 197–200
distrust of successor psychological barriers to exits 187–8
dog projects, ImmuLogic 75
domestic labour and child care women's responsibility 50
domination structures 220–22
dow Chemical, 75
coping adaptive, emotion-based, problem-based 190–91
strategy effectiveness, assess by results 193
stress regulation 189–90
corporate buyers 242
corporation for company stores 131
costs and benefits of solutions problem-based coping 190
Cox competing risks: time varying covariates 119–20
Cox proportional hazard regression model 117
craftsmen, unemployed 16
Cranet Survey 249
creativity and passion 203
credit unions, state-charted, decline 22
cross-sectional surveys and weights 108–9
data assessment 193
death/harvest/exit debate, gender blind 48
debt, unsecured 155
dominance structures 220–22
downstream, strength of 16
downward spiral of resource 15
dead capital 312
deployment of resources 16
deployment of time 16
deployment of work 16
deployment of work 16
deployment of work 16
deployment of work 16
deployment of work 16
event history analysis (EHA) methods 114–23
survival, duration, failure time, hazard 111–14
events of interest 122, 124
exit behaviour relationship 8
exit determinants 96–9
exit effort
higher, exit strategies, more value 174
importance of 176
methods need 169–174
sample activities 170
exit motives for entrepreneurs and investors 97
exit options for social ventures 214
exit outcomes 99–102
‘exit’ plan from beginning 155
exit prospects of capitalist nations 27
exit research
individual level 256
relevance 255–8
exit route, choice of 97–9
exit stage 93–4
exit strategy
differences
protection for those involved 156
VC investors and entrepreneur 97
when to begin 156
exit timing 96–7
exit vehicles, principal
IPO, acquisition, secondary sale, buy back, write-off 94
exit via partners, venture capitalists, angel investors, IPOs 239
exiting for economic reasons, ‘selling out’ 219
exits and failures 13–14
exits due to retirement, implications of 178
exits from poor or strong performance 226
exits, good or bad 42
exits, low-key 56
exits not failures 14
expansion method 131
experimental designs use research into psychological barriers 193
export out of region 253
factory production
textile and machinery industries 15
failure rates 99
family and non-family transfers, samples 193
family business context
psychological barriers to exits 187
family farming, non-violence causes, Ben & Jerry’s 221
family ownership 31
family succession 173
farms, exits to cities 16
FASTSIGNS International, Inc. 6, 130–32, 134
competition with Kinko 149
continuous growth 143–4
exit, insights from 155–6
franchise launch, 1986 134
potential merger with Kinko 148
regret at selling 154
research questions on ‘exit’ 156
trading cash for control 153
fear of mortality
in increasing age of entrepreneurs 188
psychological barriers to exits 187
female entrepreneurship, as gender bias 50
femininity of firm owners
constrained performance of business 53
finance problems for women 44
financial and production capital profit pursuing 14
financial earnings standpoint measurements for objectives 132
financial gain, exit for, ‘selling out’ 214
financial incentives for firm location 248
firm entry and exit rate, growth in productivity 255
firm exiting, Kauffman Firm Survey 111
firm interdependencies 253
firm-level research 256–7
firm migration determinants
firm or site-related factors 250
firm relocation 9
at regional level 255
findings 249–50
from region to region 246–7
size of premises factor 258
fitness, declining, retirement intention 166

Food and Drug Administration (FDA) 75, 82
formal and informal retirement preparation 167
formal connections between organizations 68
founders, exits of 13
founder’s intimacy 202–3
founder’s wealth of firm, reinvestment of 65
franchise corporate entity, setting up 133–4
franchise opportunity 133–5
franchisee qualifications and suitability 134–5
franchisees, concern for, competition with Kinko 149
franchisees, needful characteristics 135
franchising the concept, to avoid debt 133
franchisor system preparation operations manuals, marketing strategies 134
future research directions, empirical investigation 242–3
gendered influences during entrepreneurial process 46
gender, effect on business closure 4, 9, 43, 57
general or descriptive trade names, avoidance 136

General Partners (GPs), for venture capitalists 88
global economic disparities developed and developing countries 214
Global Entrepreneurship Monitor 2012
women in sub-Saharan Africa, business closures 43
global exchange networks, Europe and North America 16
goals, higher, good for exit effort 171
governance and personnel decisions 132
grass project, ImmuLogic 75
Greenfield, Jerry (Ben and Jerry’s) 221
hazard rate, risk of exit for firm 115
health care, rising costs 157
health maintenance organization (HMO), USA 19
heavy engineering, late 19th century 15
Heska Corporation, and ImmuLogic 77
high-status careers of women 58
high-technology businesses, KFS oversampling 108
hiring of young graduate for new business 131
historical eras, coverage 9, 27
HLA blocker, ImmuLogic product 78
home-based businesses of women 51
less profitability than men 55
home location choice 248–51
horse-drawn transportation 16, 22
house dust mite
Circassia research area 77
clinical trials, ImmuLogic 73
human behaviour and emotions 199
human capital 170
education, age, experience 187
endowment, enhanced, higher exit effort 171
human love, types of 201
human resource benefits 107
human rights, Body Shop 219
‘human rights and environmental issues’ 219
identity link to venture, personal characteristics 167
identity loss, fear of psychological barriers to exits 188
immigration from Europe urban workforce increase 16–17
ImmuLogic, 1987
biotechnology firm, Boston USA 70
closure, liquidation of assets 63
Malcolm L. Gefter, tenured professor 63–84
number of articles written 73
official transfers of knowledge 74
partner with Merck
  in discovery research, less success 81
partner with MMD
  on allergy program, success of 81
program duration, funding sources 74
record of patents 70–71, 75
research projects termination 63
strategic alliance with Merck 73–4
immunology, treatment for common allergies 63
immunotherapy tablets, for allergies 77
impartial third party
  importance of between business partners 144
independent VC investors 102
  preference for immediate exit routes 97
individual retirement, and entrepreneurial exit 6–7
individual women, behaviour like men, to succeed 45
individuals as units of analysis 13
individual-to-individual ties 66
individual-to-organization, two-mode networks 65–6
industrial development, mechanized production 3
Industrial Revolution 3, 15–17
  18th and 19th century 15
industry and population level 18–27
industry experience, age, education effect on exit intentions 102
inertia, structural 257
information asymmetries 94
  risk of adverse selection 88
  risk of moral hazard 88
infrastructure building 145
initial founding conditions, imprint of 35
initial public offerings (IPO) 59
  American markets 66
  exits 94, 96–8
  sale of firm shares on public market 94
  VC role 100, 102
inkjet technology 148–9
innovation and capitalist growth 11
innovations, diffusion of 3
innovative ventures, IPO exits more common 98
intellectual property, portfolio of patents 81
intellectual property protection 6, 132, 135–7
intention, for retirement
  behavioral control 164
  good reasons to 163
interests outside firm
  positive relationship with transfer 187
internal combustion engine 3
international trademarking 136
Internet-based sales and distribution 17
intimacy
  basis for friendship 205–6
  nascent venture-nascent entrepreneur relationship 202
  intimacy, passion, commitment consummate love, disengagement 206
investment selection 91–2
investors (fund providers) 5
iron and coal-mining 16
Japanese cedar project, ImmuLogic 75
jealousy and rivalry, between siblings 188
  favouritism 187
Jordan, Kim
  CEO of New Belgium Brewing Inc.
  New Belgium core values 220
Journal of Business Venturing 1
Kaplan–Meier
  product-limit method 114–15
Kauffman Firm Survey (KFS)
  businesses assigned longitudinal weight 111
data set 6
longitudinal study 107, 124
of new businesses 107–24
panel data 110
single-cohort panel 107
target population, sample design 108
keep (stay) factors
   acting as sunk costs 253
   employee retention 253
   unwillingness to relocate 257
knowledge
codification, after partnership 81
   localized 253
   spillover effects of firms in region 255
knowledge-based sectors of economy 36
labour market areas (LMA), US 247–8
labour market positioning for women 48–9
lease negotiation 129, 131
legacy creation
   philanthropic and pro-social behaviors 172
legacy leaving in entrepreneurial exit 172
   retirement intention strong 172
   legal protection 132
   legal ramifications of partnerships 141–5
   insights from 144
legitimation structures 219–20
   values for dispensing rewards 216–17
LexisNexis
database for newspaper and other articles 72
life-cycle perspective 83, 150, 157, 254
life tables, construction 115
life tables example 117
Limited Partners (LPs) for investors 88
loans, short and long-term
   commercial entrepreneur 233
logit response models, multinomial approach to competing risks 122
L’Oréal
cosmetic group, no testing on animals 220
love, triangular theory of 206–7
   intimacy, passion and decision, commitment 199
   strong feelings for ventures 199
   love, types of, and evolution of 208
loving relationship between founders and their ventures 200–202
low cash reserves, threat to social venture 233–4
managerial and human resource issues 37
managerial control, for firm’s social goals 239–40
managerial roles, results of exit 231
managing relationships, insights from 139
Marine Hospital Service, USA, prepaid medical care 19
mass production in manufacturing automobiles, home appliances 16
Massachusetts Institute of Technology (MIT) 63
maternal health issues in developing countries 215
maternal responsibilities, not all women 58
mechanization, textile and machinery industries 15
medium-technology businesses
   KFS oversampling 108
MEDLINE database
   record of authors for ImmuLogic 71–2
meeting with partner’s family and attorney 142–3
mental disengagement, coping behavior 191
mergers and acquisitions (M&A) 1, 96–8, 242
Metropolitan Statistical Areas, US 247
microelectronics 3, Middle East and North Africa (MENA)/Mid-Asia region
   fewer start-ups from women 43
Millennium Pharmaceuticals 76
mission-driven entrepreneur 214, 219
   preservation of original values 223
   model of van Teeffelen
      on transfer, pre and post transfer phases 186
money investment, assumptions 233
money or control 150–53
moral hazard risk 88–9
Morgenstern, contact for allergy program 76
motivation and behaviors of partner 139–40
multi-episode – longitudinal data 113–14
multiple sclerosis, ImmuLogic work on 78–9
name change, SIGNWAVE 136
nascent entrepreneurial disengagement 197–201, 205
National Foundation of Independent Businesses (NFIB) 1
National Institute of Health (NIH) 79 funding for research 71
National Institute on Drug Abuse (NIDA) 79–80
National Venture Capital Association (NVCA) 96
natural capitalism 214–15
natural personal hygiene goods, Tom’s of Maine 218
negation of ‘continuation’ 198
negative cash flow, threat to social venture 233–4
network perspective 65–7, 83
network reconfiguring after exit 69–70
New Belgium Brewing Company 8
partnerships with microbrewing companies 220
wind energy use, water conservation program 220
new ventures, survival or non-survival 29, 197
newness, liability of 30
estimate for PSEDII sample 32
social capital, retirement intentions 31
non-informative (random) censoring 112
nonparametric analysis
Kaplan–Meier and Life Tables 114
normative exit routes 56
offer of 20% ownership after sale of FASTSIGNS 150–51
Office of Extramural Research
National Institutes of Health (NIH) 71
oil, automobile, mass production early 20th century 15
operational firms 209
opportunities discovery 217–22
optimism of entrepreneurs 177
ordinary least squares (OLS) 112
organizational emergence process 28
organization level 27–37
organizations, connections between a network type 66
organization-to-organization tie 66–7
owner ill-health, business exits 44
owner-operators, active 107
ownership autonomy, better for time management 53
ownership transfer failure, 40 per cent 185
ownership transfer success, assessment of 193
Panel Study of Entrepreneurial Dynamics (PSED)
liability of newness 30–31
parametric analysis of duration data 114, 118–21
parametric proportional hazards (PH) 118
parametric regression, time-varying covariates 125–6
parent-child analogy 81–2
partial buyback
sale of part of VC investor’s holdings 95
partial exit of social entrepreneur retaining majority ownership 238–9
partners and franchises 4
importance of close connection with 150
partner sexual misbehaviour, costs involved 145–6
partnership agreement
partner’s stock bought before death 143
part-time businesses of women 51
passion 205–8
source of motivational arousal 203–4
Patagonia Inc. 218
patent driven research stream, ImmuLogic funding 75
Index

patent protection of intellectual property 170
patents of ImmuLogic, 64, 73
personal connections
individuals from multiple organizations 65
individual-to-organization connections 66
personal embeddedness 67–8
personal network of entrepreneur 67–8
personal responsibilities in business venture 130
personal variables 176
personnel issues, relocation in US 131–2
philosophy of business
financial security vehicle 156
Point Therapeutics, staff move from ImmuLogic 76
policy initiatives, on firms’ relocation 258
population aging in developed nations
research on retirement 158
population decline, excess of exits over entries, 22
‘population density’ 18–20, 258
population growth and decline, 27 in 23 US industries 21
populations, organizational
major decline examples in US 23
positive associations with retirement optimal exit strategy 175
women’s position on this 56
positive reinterpretation, coping behavior 191
post-investment monitoring 92–3
postponement risk of business transfer
incompetent successor chosen on purpose 185
incumbent refusal to delegate 185
lagging of investment 184
liquidation 184
unavailability of successor 184
post-retirement options 157
prejudice against succession planning
psychological barriers to exits 188
price offer assessment, coping behavior 190
primary wage earners, social pressures on men 55
Principal Registration, for trade names, US 136
private equity activity, definition 90
private equity funds, closed-end nature 93
private equity (PE) 151–5
problem definition, problem-based coping 190
product license application (PLA) 75
product market competition 98
projected marginal costs (PMC) 96
projected marginal value added (PMVA) 96
psychological barriers, in business transfers 184–93
copeing strategies 192
psychological barriers, known 187–9
psychological barriers to exits 7, 9
connection with types of coping 192–3
detection of 189
further understanding 189
literature on 185–7
psychological ownership, higher lower retirement intention 167–8
psychology 37
pull factors for relocation 257
proximity to customers, or raw materials 252–4
push factors for relocation, lack of growth space 252
quality of exit opposed to harvest amount 242
R&D alliances 66
R&D investment in biotechnology company 66
ragweed allergies, ImmuLogic 75
railway operating decline 22
railways, introduction of 3
railways and steam 15–16
random censoring 112
RBV see resource-based view
recession of 2008 12, 32–3
refinancing fees 153
regional clusters for manufacturing firms 253
regional embeddedness 249
identity link to venture 163
intention behaviors 170–71
non-work factors 161
positive attitudes towards health,
wealth gender (male), and age
166
positive effect on exit effort 171
push or pull factors 161–2
reasons for 159, 165–9
research model 164–5, 174–5
result in exit strategy 175
theoretical perspectives 160
work-related factors 161
return on assets (ROA) 101
return on investment (ROI) 221
rheumatoid arthritis treatments 78
right-censored cases in KFS, patterns of 113
right-censoring of data 31, 112
risk of nascent entrepreneur
disengagement 204
Roddick, Anita
Body and Soul (1991) 219
‘social and environmental change’
219
The Body Shop, sale to L’Oréal 215
role change and degradation of power
psychological barriers to exits 187–8
role regard, positive or negative
assessments 167
sale of existing businesses, of both
partners 131
sale of FASTSIGNS 152–3
sale or liquidation 173
sales objective, financial 131
scientific advisory board (SAB)
members 82
secondary sale of VC investor’s shares
95–6
Security Exchange Commission (SEC)
ImmuLogic’s corporate history 71–2
seed stage investors
undeveloped technology and concept
89
self-efficacy of entrepreneurs 177
self-regulation of entrepreneurs 177
seller’s perspective of deal, investigation 242
sensitivity counselling for business staff member 145
Shane and Venkataraman, entrepreneurial process 226
shareholder and partnership agreement upon 130
shareholders’ agreement life insurance, buyout mechanism 137
partner, prior resistance and difficulties 137–8
reluctance of one partner 131
shoes, sold, pair given to child in need Argentinian-inspired 236
signage, computer generated successful sales 132
signification structures 217–19
meaning in social interactions 216–17
sign makers, hiring of 131–2
single-episode — longitudinal data 113
site selection 129, 139
size of firm, influence on relation 250
social and commercial ventures four differences 232
social and professional relationships 82–3
social and sustainable ventures 221
social capital, importance in home region 251
social embeddedness, keep factor 253
social entrepreneurs 8, 214, 218, 226
altruistic objectives for exit 232
how they exit social ventures 14–18, 226–43
literature 241
motivations for exit 230–32
reasons for exit 231
resource-based view (RBV) 229
successful exits for 214
theoretical background 229–30
timing of exits 243
social goals pursuing, no guarantee 238
social goals serving exit as conceivable motivation 236
social mission firms 215, 218
social purpose of venture, exit less likely 218, 220
social relationships data, ImmuLogic 80
social responsibility, Body Shop 219
social skills, tenacity, achievement need of entrepreneurs 177–8
social support, coping behavior 191
social values competition with economic values exit less likely 220
social ventures 214–23
attacking social issues 226
exit examples 8, 227
social vision, need to live on 234
social wealth increase 214
society-level emergence and exit 15
socio-economic context women’s disadvantaged position 49, 53
socio-economic framework of society inertia 14
’spectacular’ failures, societal stigma, sense of loss 57
staff hiring interviews 140
staff scientists 82
staff training system 147
staged financing 92
stakeholder reactions to retirement 178
stand-alone analysis 108
start-up phase, disengagement from 197
start-up process, commitment importance 204
start-up year, Kauffman Firm Survey 111
state-chartered credit unions decline New York 23
steam and railways, early to mid-19th century 3, 15–16
stock market conditions crucial for IPO’s VC backed timing 94
stock method of payment 95
store design and opening 129, 131
stores, second and third, opening in other towns in Texas 133
stress, effective dealing importance in entrepreneurship 190

Research handbook of entrepreneurial exit

structuration theory 8
entrepreneurial exit of social ventures 222
interdependence of context (structure) and actor (agent) 216
substance abuse program 79–80
substance use, coping behavior 191
success in start-up teams 130
succession planning, prejudice against tendency not to plan 187
sunk costs 253
Supplemental Registration, for trade names, US 136
support of business owner 139
suppression of competing activities coping behavior 191
survival function, Kaplan–Meier estimate 31
‘survival probability’ definition 29

team relations 130
team start-ups 29, 209
technological change, emergence of new industries 14
technological innovations, late nineteenth century 15–16
telecommunications 3, 17
late 20th century 15
temporal stability 172–3
The Body Shop, structuration theory 8
theory of planned behavior (TPB) 158, 176–7
testing 208
time and energy investment, assumptions 232–3
time management 146
time models of duration 121–2
timekeeping, careless 140
timelines for ImmuLogic 73
time-to-event data 111–12
methods for analysing 114
tire industry, US, 1900–1980
entry and exit rates 24–6
Tom’s of Maine. structuration theory 8
non-phosphate laundry detergent sales 218
sale to Colgate/Palmolive 215
‘Tom’s: Shoes for Tomorrow’ for-profit venture. ‘alpargata’ shoes 236–7
toothpaste, all-natural, Tom’s of Maine 218
total entrepreneurial activity (TEA) 43
total factor productivity (TFP) 93
trade associations 36
trade sale of entrepreneurial firm to another company 95
trade sales exits 96
trademarking, insights from attorney in field 136
clear view of costs 136
trademarking of names 134–7
transportation, long-distance handicraft goods, locally produced 16
travel and insurance agencies 17
triple-bottom-line performance economic, environmental, social success 215
twenty-first century, early genomics and bio-informatics 17
types of analyses, Kaplan–Meier graphs 6
underpricing 100
unemployment insurance tax accounts 32
online database of patents 70
Unilever, consumer products company Ben & Jerry’s right to sue 221
Ben & Jerry’s sold to, by shareholders 221
VRIN resources from Ben & Jerry’s 235
Unilever, protection of current employees 240
United States Patent and Trademark Office (USPTO)
units of analysis 12–14
US railways decline 23
vaccine against cocaine, ImmuLogic 79
vaccines for substance abuse 63
value-adding activities, control mechanism of VC 92
values 219–20
centrality of, for social entrepreneurs 219
variability, evolution and innovation 37
positive association with company performance 101
Venkataraman (1997) resource acquisition and utilization 221
venture capital (VC) active management of entrepreneurial firm 88
exit stage 87–103 financing process 91–6 formal and informal 89 funding 9, 88 investments 5 investor characteristics and exit outcome 99 investor, role at exit stage 100–101 investor types captive VCs (CVCs) 102 independent VCs (IVCs) 102 investor’s role after exit stage 101–2 reputation 99 investment duration comparison of USA and Europe 96–7 investments 88 positive influence on firm employees, sales growth 93 partnership with firm 88 role at exit stage 99–102 seed stage investors 89 venture creation stage, social networks 5 venture dependence on entrepreneur low retirement intention 169 vinyl applications 148–9 voting power of VC investors 92 VRIN resources negative relationship with intention to exit 237 outside of social venture 236–7 outside social firm 234–7 waged employment for women cause of entrepreneurial exit 54 waged employment, good quality more suitable for women 52 waged employment, lower returns women-owned firms 51 Wedgewood pottery 15 weights, provision by KFS longitudinal and cross-sectional 108–11 women and self-employment in UK 43 women as secondary earners 55 women entrepreneurs, fewer ‘spectacular’ failures 57 women seen as limited performers in entrepreneurial projects 50 women-owned businesses alleged ‘problems’ 53 from home or part-time 49 women’s exclusion by child care responsibilities 55 women’s exits less profitability than men 43–4 work as source of self-identity 166 work behavior 107 working definitions of important issues time, agreements, delivery of 140 work-role attachment job involvement, company identification 166 World Wide Web 3 write-off, full implication of bankruptcy of firm 95 write-off, partial 95 young firms, interregional choices 250